Navigation Links
Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009
Date:8/13/2009

of 2008. Consistent with second quarter results, the increase was primarily attributable to $544,000 of grant revenue related to the IPLEX(TM) MMD clinical trial recorded during the most recent six-month period. This was partially offset by a decrease of $262,000 in cost recovery from the various Expanded Access and Named Patient Programs to treat patients with Amyotrophic Lateral Sclerosis ("ALS"), also known as Lou Gehrig's Disease, in Europe.

Net income for the six months ended June 30, 2009 was $116.2 million, or $0.93 per share, compared to a net loss of $9.5 million, or $0.08 per share, for the first six months of 2008. This $125.7 million improvement was primarily due to the $127.8 million before tax gain on sale of our FOB assets to Merck, a $3.6 million decrease in R&D expenses and the $0.3 million rise in total revenues, which were partially offset by a $3.3 million increase in SG&A expenses and $2.8 million in income tax expense on the sale of our FOB assets. Year-over-year, R&D expenses fell to $7.3 million for the first half of 2009 from $10.9 million, reflecting a decrease in manufacturing expenses following the sale of our FOB assets in March 2009. SG&A expenses increased to $6.3 million for the first half of 2009 from $3.0 million a year earlier, due largely to the recognition of stock compensation expense for the restricted stock and restricted stock units that vested on March 31, 2009, and the award of bonuses, together with the increased consulting, personnel and license fees previously mentioned.

Interest income for the first half of 2009 was $135,000 and was a reduction from the $375,000 earned in the same period of 2008 due to lower interest rates.

"We remain focused on leveraging our strong balance sheet to grow our business and enhance shareholder value," said Dr. Melvin Sharoky, Insmed's Chairman. "The entire Board and management team, along with our strategi
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Insmed Provides Update on Supply of IPLEX(TM)
2. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
3. Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
4. Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants
5. Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs
6. Insmed to Present at Upcoming Healthcare Conferences
7. Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
8. Westaim announces 2009 second quarter results
9. eDiets.com(R) Announces Q2 2009 Results
10. Nutrition 21 Announces Preliminary Fourth Quarter Financial Update Also Announces Negotiations on Notes due August 25, 2009
11. Procter & Gamble Announces Appointment of Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 The report “Stivarga (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... a drug which is used in the treatment of ... and is also prescribed to patients who suffer from ... approved is a multi-kinase inhibitor and it blocks many ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) ... one year will be allowed to donate blood in the United ... ban on donations from men who have sex with men. ... release a new draft guidance in early 2015 that would ultimately ... FDA is changing its policy based on data from other countries ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A new, ... Food and Drug Administration. The agency on Tuesday ... for those who are overweight and have at least ... type 2 diabetes or high cholesterol. Patients taking ... a low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle HealthDay Reporter ... are more likely to start smoking or drinking with ... (ADHD) or conduct disorder, new research suggests. ... the risk of substance use as [these] children approach ... at Cincinnati Pediatric Research Group, which is part of ...
(Date:12/24/2014)... Gluten, a protein found predominately in wheat ... intolerance to gluten, causing side effects that can range ... pain and fatigue. For this reason, Diet Doc created ... safe and fast weight loss while teaching patients how ... reaction. These gluten free diet plans combine the healthiest ...
Breaking Medicine News(10 mins):Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... ... orthodontist, Dr. Inna Gellerman, kicks off holiday season with food drives, toy drives and ... ... , Dr. Inna Gellerman, celebrates the holiday season by participating in various community events, ...
... ... Medtronic founder, joins Dr. Jean Watson to launch The Million Nurse Global ... www.millionnurseproject.org ! . Nurses are uniting to celebrate the 2010 ... and two proposed United Nations Resolutions, together to radiate heart-centered Love and ...
... , ... With over 45 million uninsured in the ... Obama’s plans for health insurance reform in the United States, one ... transcends traditional boundaries. MediBid connects physicians to patients in a free-market ...
... ... has announced that they have added a new line of Natural ... Vitamins are produced on FDA registered and inspected facility operating since ... Medicine’s Nutritional vitamins and supplements make them safe, top quality products. ...
... ... company and "Top 100" Rochester, NY Growth Company, is partnering with AstraZeneca ... for the improved management of hypertension. The partnership program positions community ... a select group of Canadian retail pharmacy participants. , ...
... , AUBURN HILLS, Mich., Dec. ... integrated logistics services and highly customized supply chain solutions ... Worldwide Holdings, Inc. The terms of the transaction are ... , Addison, IL-based NAL is a third-party logistics (3PL) ...
Cached Medicine News:Health News:Long Island Children's Orthodontist, Dr. Inna Gellerman, Celebrates Season of Giving with Holiday Drives and Events 2Health News:The Million Nurse Global Caring Field Project Launches Jan. 1st, 2010 at Noon 2Health News:MediBid.com Empowers Physicians to Expand Their Fee for Service Practice with New Online Portal 2Health News:MediBid.com Empowers Physicians to Expand Their Fee for Service Practice with New Online Portal 3Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 2Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 3Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 4Health News:PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management 2Health News:syncreon Acquires NAL Worldwide Holdings Inc. 2Health News:syncreon Acquires NAL Worldwide Holdings Inc. 3
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... 2014 Apnea Sciences ( www.apneasciences.com ) announced ... Aliso Viejo , California.  Jimmy Fallon ... growth and worldwide expansion, a new facility with expanded ... anti snore cure have exceeded our expectations and thus ... now in 23 countries and will be increasing to ...
(Date:12/22/2014)... Dec. 22, 2014   TRU-D SmartUVC LLC, ... disinfection robot, announced today that the General Services Administration ... November 2019.   This newly formed agreement ... levels of government purchasers, including Department of Veteran Affairs ... Homeland Security contacts purchasing solutions for the Ebola effort ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... 23, 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ... infringement lawsuit against Santaris Pharma A/S and Santaris Pharma ... the Southern District of California.  Isis, infringement suit against ... and antisense drug discovery services to several pharmaceutical companies. ...
... Sept. 23, 2011 Amgen (NASDAQ: AMGN ... Vectibix® (panitumumab) studies will be presented at the 2011 ... in Stockholm, Sweden.   "The data being ... Amgen,s ongoing commitment to advancing the understanding of cancer ...
Cached Medicine Technology:Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma 2Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma 3Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 2Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 3Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 4Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 5Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 6Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 7Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 8Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 9Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 10
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: